Premier Anti-Aging Co., Ltd.
Financial Summary
For the consolidated net sales for the fiscal year ending July 2026, YoY decline overall; Recovery Business grows, Anti-Aging Business declines. Operating income exceed the revised plan. For 2027/07, company-wide sales are expected to be at the prior year’s level, but operating income is anticipated to decline due to greater brand investment and new product launches. Segment-wise, continued growth focus on duo-related promotions and expansion of Recovery, with育成 brands such as Canadel and Clayence continuing to be developed.
Key Figures
- Sales: 13,883 million yen
- Operating income: 494 million yen
- Net income attributable to owners of parent: 364 million yen
AI要約
Overview of Performance
For the fiscal year ending July 2026, consolidated net sales are supported by growth in the Recovery Business, but decline due to weaker Anti-Aging product sales. Operating income progressed as costs were controlled and promotional investments for new products exceeded plans. Segments continue to expand promotions for Duo and broaden wholesale/EC channels;育成 brands such as Canadel and Clayence remain in development. Recovery Business maintains growth through offline sales expansion. For the fiscal year ending July 2027, company-wide sales are assumed to be at the previous year's level, but operating income is expected to decline due to expanded brand investments and new product launches.
Outlook and Strategy
Proceed with a full-scale rollout of Skin for Longevity as the core of the skincare portfolio. By optimizing the channel mix across offline and digital and strengthening CRM, aim to improve LTV and brand awareness. The Recovery Business will continue to lead market growth. Financially, continue to optimize advertising/promo expenses and reduce fixed costs, with plans to balance growth investments and profitability in 2027.
Premier Anti-Aging Co., Ltd.
Company overview · Stock price · Financial data · All IR
